7 results
SGLT2 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits SGLT2 (sodium/glucose cotransporter 2) in the proximal tubule,
- Pharmacology ... heart disease • All ... #Pharmacology # ... Summary #DM2 #diabetes ... #endocrinology
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
DPP-4 Inhibitors ... - Pharmacology ... #Pharmacology # ... Summary #DM2 #diabetes ... #endocrinology
Pituitary Mass Effects - Pathogenesis and Clinical Findings
 • Pituitary turnors are almost always a benign
masses of all sizes ... Signs / Symptoms ... Hyperprolactinemia • Diabetes ... #SideEffects #endocrinology ... mnemonic #GLFTAP #pathophysiology
SGLT2 Inhibitors 
SGLT2 inhibitors are the newest class of anti-diabetic medications, with the first one (Canagliflozin)
SGLT2 Inhibitors ... class of anti-diabetic ... #Pharmacology # ... Medications #DM2 ... #Diabetes #Endocrinology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Sulfonylurea, TZD, DPP-4 inhibitor ... α-glucosidase inhibitor ... #Mellitus #DM2 ... #Medications #pharmacology ... comparison #table #endocrinology
DPP4 Inhibitors - Normal and Renal Dosing

Increase Incretins (GLP-I & GIP) -> Stimulates Insulin, Inhibits Glucagon
DPP4 Inhibitors ... Stimulates Insulin, Inhibits ... Renal #Dosing #Pharmacology ... #Management #Diabetes ... #DM2 #Endocrinology
Management of Anthracyclines and HER2 Antagonist Cardiotoxicity
Anthracyclines cause cardiomyopathy:
 ✖ Reduction in left ventricular ejection fraction
, 350 mg/m2, and ... system (RAAS) inhibitor ... hypertension, diabetes ... after 4 cycles for all ... cardiology #oncology #pharmacology